Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Di Maio

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
ESMO Open|April 17, 2024
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experienceR Moretto, M M Germani, B Borelli, et al.
British Journal of Cancer|May 27, 2004
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancerM Di Maio, C Gridelli, C Gallo, et al.
ESMO Open|January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trialF Piscaglia, G Masi, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control studyC Cremolini, F Morano, R Moretto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2018
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016L Marandino, A La Salvia, C Sonetto, et al.
ESMO Open|June 12, 2025
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)A Rossi, A G Leone, M Lambertini, et al.
Current Pharmaceutical Design|April 12, 2002
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trialF Perrone, C Gallo, B Daniele, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Journal of Endocrinological Investigation|June 27, 2024
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical viewA Natalicchio, N Marrano, M Montagnani, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
ESMO Open|April 17, 2024
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experienceR Moretto, M M Germani, B Borelli, et al.
British Journal of Cancer|May 27, 2004
Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancerM Di Maio, C Gridelli, C Gallo, et al.
ESMO Open|January 28, 2025
Atezolizumab plus bevacizumab as first-line treatment of unresectable hepatocellular carcinoma: interim analysis results from the phase IIIb AMETHISTA trialF Piscaglia, G Masi, E Martinelli, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control studyC Cremolini, F Morano, R Moretto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 11, 2018
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016L Marandino, A La Salvia, C Sonetto, et al.
ESMO Open|June 12, 2025
Sexual health in cancer care: a narrative review and position statement from the Italian Association of Medical Oncology (AIOM)A Rossi, A G Leone, M Lambertini, et al.
Current Pharmaceutical Design|April 12, 2002
Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trialF Perrone, C Gallo, B Daniele, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2021
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapyE Ghisoni, A Wicky, H Bouchaab, et al.
Journal of Endocrinological Investigation|June 27, 2024
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical viewA Natalicchio, N Marrano, M Montagnani, et al.
ESMO Open|June 20, 2025
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trialR Fazio, G Randon, F Bergamo, et al.
Pageof 9